{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:47:06Z","timestamp":1793674026247,"version":"4.5.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016338","name":"Imperial Experimental Cancer Medicine Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lanepe.2026.101839","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:48:00Z","timestamp":1788479280000},"page":"101839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe"],"prefix":"10.1016","volume":"70","author":[{"given":"David J.","family":"Pinato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Alimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7189-3035","authenticated-orcid":false,"given":"Antonia","family":"Digklia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9681-2542","authenticated-orcid":false,"given":"Najib","family":"Ben Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4904-5133","authenticated-orcid":false,"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Presa","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grainne M.","family":"O\u2019Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cappuyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8104-6585","authenticated-orcid":false,"given":"Giulia","family":"Tesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lanepe.2026.101839_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10126","key":"10.1016\/j.lanepe.2026.101839_bib2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"10064","key":"10.1016\/j.lanepe.2026.101839_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101839_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101839_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101839_bib6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101839_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101839_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (checkMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanepe.2026.101839_bib9","article-title":"Systemic management of advanced HCC: an increasingly complex game","volume":"7","author":"Martirena","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101839_bib10","article-title":"Efficacy of atezolizumab plus bevacizumab for unresectable HCC: systematic review and meta-analysis of real-world evidence","volume":"7","author":"Manfredi","year":"2025","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101839_bib11","article-title":"Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: results of the DT-real study","volume":"8","author":"Celsa","year":"2026","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101839_bib12","article-title":"Atezolizumab\/bevacizumab or lenvatinib in hepatocellular carcinoma: multicenter real-world study with focus on bleeding and thromboembolic events","volume":"6","author":"Ben Khaled","year":"2024","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101839_bib13","article-title":"Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC","volume":"8","author":"Ben Khaled","year":"2026","journal-title":"JHEP Rep"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101839_bib14","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/apt.70090","article-title":"Therapeutic sequences of systemic therapy after Atezolizumab plus Bevacizumab for hepatocellular carcinoma: Real-world analysis of the IMMUreal cohort","volume":"61","author":"Ben Khaled","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.lanepe.2026.101839_bib15","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.annonc.2025.05.161","article-title":"Overall evaluation of health-related quality of life (HRQoL) and efficacy assessment in patients (pts) who discontinued (d\/c) due to treatment-related adverse events (TRAEs): results from CheckMate 9DW","volume":"36","author":"Sangro","year":"2025","journal-title":"Ann Oncol"},{"issue":"10408","key":"10.1016\/j.lanepe.2026.101839_bib16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"7854","key":"10.1016\/j.lanepe.2026.101839_bib17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"10541","key":"10.1016\/j.lanepe.2026.101839_bib18","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(26)00138-8","article-title":"Implementing sustainable liver health in Europe: a second EASL-Lancet Commission","volume":"407","author":"Karlsen","year":"2026","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101839_bib19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101839_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101208","article-title":"Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries","volume":"8","author":"Post","year":"2023","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101839_bib21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jamaoncol.2024.2166","article-title":"Immunotherapy vs best supportive care for patients with hepatocellular cancer with child-pugh B dysfunction","volume":"10","author":"Fulgenzi","year":"2024","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101839_bib22","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/jamaoncol.2023.3284","article-title":"Immune checkpoint inhibitors for child-pugh class B advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"9","author":"Xie","year":"2023","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101839_bib23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.lanepe.2026.101839_bib24","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101839_bib25","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101839_bib26","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"23","key":"10.1016\/j.lanepe.2026.101839_bib27","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.23.01462","article-title":"Patient-reported outcomes from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"42","author":"Sangro","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101839_bib28","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"issue":"10492","key":"10.1016\/j.lanepe.2026.101839_bib29","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101839_bib30","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101839_bib31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2023.10.040","article-title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","volume":"80","author":"Celsa","year":"2024","journal-title":"J Hepatol"},{"issue":"10088","key":"10.1016\/j.lanepe.2026.101839_bib32","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101839_bib33","article-title":"Second-line pembrolizumab for advanced HCC: meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies","volume":"7","author":"Finn","year":"2025","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101839_bib34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.annonc.2024.03.005","article-title":"Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040","volume":"35","author":"Melero","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101839_bib35","article-title":"Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN study","volume":"7","author":"Lombardi","year":"2025","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101839_bib36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jhep.2025.08.020","article-title":"Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab","volume":"84","author":"Kim","year":"2026","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101839_bib37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000543666","article-title":"Multicenter phase 2 trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on Atezolizumab plus Bevacizumab","volume":"14","author":"Cheon","year":"2025","journal-title":"Liver Cancer"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101839_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jhep.2024.03.033","article-title":"Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment","volume":"81","author":"Chan","year":"2024","journal-title":"J Hepatol"},{"issue":"16_suppl","key":"10.1016\/j.lanepe.2026.101839_bib39","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1200\/JCO.2026.44.16_suppl.4002","article-title":"IMbrave251: final analysis of atezolizumab (atezo) + lenvatinib (lenva) or sorafenib (sora) vs lenva or sora alone in locally advanced or metastatic hepatocellular carcinoma (LA\/mHCC) previously treated with atezo and bevacizumab (bev)","volume":"44","author":"Vogel","year":"2026","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.lanepe.2026.101839_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e16150","article-title":"CVM-1118: a potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)\u2014A phase IIa study","volume":"42","author":"Yen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.lanepe.2026.101839_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2675","article-title":"ATHENA: a phase 1\/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced\/recurrent hepatocellular carcinoma (HCC)","volume":"42","author":"Hamilton","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.lanepe.2026.101839_bib42","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2026.44.16_suppl.4015","article-title":"Tegavivint, a downstream Wnt\/\u03b2-catenin inhibitor: dose-finding results from a phase 1\/2 trial in advanced hepatocellular carcinoma (aHCC)","volume":"44","author":"Hsieh","year":"2026","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101839_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0321189","article-title":"Study protocol: fecal microbiota transplant combined with Atezolizumab\/Bevacizumab in patients with hepatocellular carcinoma who failed to achieve or maintain objective response to Atezolizumab\/Bevacizumab - the FAB-HCC pilot study","volume":"20","author":"Pomej","year":"2025","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101839_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101839_bib45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101839_bib46","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101839_bib47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","article-title":"Molecular pathogenesis and systemic therapies for hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2022","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101839_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101839_bib49","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101839_bib50","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jhep.2023.08.017","article-title":"Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab\/bevacizumab","volume":"79","author":"Limousin","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101839_bib51","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41416-019-0466-x","article-title":"Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study","volume":"120","author":"Pinato","year":"2019","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101839_bib52","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101839_bib53","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","article-title":"Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma","volume":"82","author":"Cappuyns","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101839_bib54","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2025.04.017","article-title":"Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma","volume":"83","author":"Vithayathil","year":"2025","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101839_bib55","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","article-title":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score","volume":"76","author":"Scheiner","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101839_bib56","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101839_bib57","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-24-0177","article-title":"Safety and preliminary efficacy of pembrolizumab following transarterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study","volume":"30","author":"Pinato","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10474","key":"10.1016\/j.lanepe.2026.101839_bib58","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"10474","key":"10.1016\/j.lanepe.2026.101839_bib59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"issue":"17_suppl","key":"10.1016\/j.lanepe.2026.101839_bib60","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA4000","volume":"44","author":"Abou-Alfa","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101839_bib61","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.annonc.2025.05.542","volume":"36","author":"Dong","year":"2025","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101839_bib62","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1200\/JCO-25-01796","article-title":"Transarterial chemoembolization combined with camrelizumab and rivoceranib for unresectable hepatocellular carcinoma (CHANCE2005\/CARES-005): a randomized phase II trial","volume":"44","author":"Zhu","year":"2026","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101839_bib63","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3350\/cmh.2025.0724","article-title":"Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma","volume":"31","author":"Lee","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101839_bib64","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101839_bib65","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","article-title":"Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study","volume":"7","author":"Kim","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101839_bib66","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"issue":"19","key":"10.1016\/j.lanepe.2026.101839_bib67","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101839_bib68","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101839_bib69","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2967\/jnumed.123.266211","article-title":"Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial","volume":"65","author":"Garin","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.lanepe.2026.101839_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2026.103884","article-title":"Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients","volume":"95","author":"Guiu","year":"2026","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101839_bib71","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1097\/JS9.0000000000002326","article-title":"Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"111","author":"Lu","year":"2025","journal-title":"Int J Surg"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101839_bib72","first-page":"779","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"issue":"3","key":"10.1016\/j.lanepe.2026.101839_bib73","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101839_bib74","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41571-026-01160-z","article-title":"Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement","volume":"23","author":"Llovet","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101839_bib75","article-title":"Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association","volume":"57","author":"Allaire","year":"2025","journal-title":"Lancet Reg Health Eur"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:18:27Z","timestamp":1793632707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226002516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":75,"alternative-id":["S2666776226002516"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101839","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101837","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101861","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101852","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101839"}}